keyword
MENU ▼
Read by QxMD icon Read
search

III stage colon cancer

keyword
https://www.readbyqxmd.com/read/28101757/final-report-of-kscc0803-feasibility-study-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer-in-japan
#1
Kazuhito Minami, Masaru Morita, Yasunori Emi, Masahiro Okamoto, Eiji Tanaka, Shigeyuki Nagata, Tetsuo Touyama, Kippei Ohgaki, Takaho Tanaka, Hiroshi Okumura, Toyokuni Suenaga, Shoji Tokunaga, Eiji Oki, Yoshihiro Kakeji, Yoshito Akagi, Hideo Baba, Shoji Natsugoe, Yoshihiko Maehara
BACKGROUND: The impact of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected colon cancer was unclear. We previously planned and conducted a prospective feasibility study (KSCC0803) and reported on the safety of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected stage III colon cancer. The purpose of the current study was to assess the survival results from that study. METHODS: The study subjects were Japanese patients with resected stage III colon cancer...
January 18, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28101721/quantitative-assessment-of-visceral-obesity-and-postoperative-colon-cancer-outcomes
#2
Oluwatobi O Ozoya, Erin M Siegel, Thejal Srikumar, Amanda M Bloomer, Amanda DeRenzis, David Shibata
BACKGROUND: Quantitative computed tomography (CT) assessment of visceral adiposity may be superior to body mass index (BMI) as a predictor of surgical morbidity. We sought to examine the association of CT measures of obesity and BMI with short-term postoperative outcomes in colon cancer patients. METHODS: In this retrospective study, 110 patients treated with colectomy for stage I-III colon cancer were classified as obese or non-obese by preoperative CT-based measures of adiposity or BMI [obese: BMI ≥ 30 kg/m(2), visceral fat area (VFA) to subcutaneous fat area ratio (V/S) ≥0...
January 18, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28088321/surgeon-pathologist-and-hospital-level-variation-in-suboptimal-lymph-node-examination-after-colectomy-compartmentalizing-quality-improvement-strategies
#3
Adan Z Becerra, Christopher T Aquina, Mariana Berho, Francis P Boscoe, Maria J Schymura, Katia Noyes, John R Monson, Fergal J Fleming
BACKGROUND: The goals of this study were to characterize the variation in suboptimal lymph node examination for patients with colon cancer across individual surgeons, pathologists, and hospitals and to examine if this variation affects 5-year, disease-specific survival. METHODS: A retrospective cohort study was conducted by merging the New York State Cancer Registry with the Statewide Planning & Research Cooperative System, Medicaid, and Medicare claims to identify resections for stages I-III colon cancer from 2004-2011...
January 11, 2017: Surgery
https://www.readbyqxmd.com/read/28087988/cpg-island-methylator-phenotype-is-an-independent-predictor-of-survival-after-curative-resection-for-colorectal-cancer-a-prospective-cohort-study
#4
Chang Hyun Kim, Jung Wook Huh, Hyeong Rok Kim, Young Jin Kim
BACKGROUND AND AIMS: The CpG island methylator phenotype (CIMP) is found in approximately 30% of colorectal cancer (CRC) cases. However, the role of CIMP status in predicting oncologic outcomes in curatively resected CRC is still unclear. STUDY: Between January 2006 and December 2006, we retrospectively reviewed 157 consecutive patients who underwent curative surgery for CRC. Prognostic significance of CIMP status was evaluated using reverse transcriptase-polymerase chain reaction...
January 14, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28081292/the-utility-of-abbreviated-patient-reported-outcomes-for-predicting-survival-in-early-stage-colorectal-cancer
#5
Tina Hsu, Caroline H Speers, Hagen F Kennecke, Winson Y Cheung
BACKGROUND: Patient-reported outcomes (PROs) are increasingly used in clinical settings. Prior research suggests that PROs collected at baseline may be associated with cancer survival, but most of those studies were conducted in patients with breast or lung cancer. The objective of this study was to determine the correlation between prospectively collected PROs and cancer-specific outcomes in patients with early stage colorectal cancer. METHODS: Patients who had newly diagnosed stage II or III colorectal cancer from 2009 to 2010 and had a consultation at the British Columbia Cancer Agency completed the brief Psychosocial Screen for Cancer (PSSCAN) questionnaire, which collects data on patients' perceived social supports, quality of life (QOL), anxiety and depression, and general health...
January 12, 2017: Cancer
https://www.readbyqxmd.com/read/28078540/preplanned-safety-analysis-of-the-jfmc37-0801-trial-a-randomized-phase-iii-study-of-six-months-versus-twelve-months-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer
#6
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita
BACKGROUND: Six months of adjuvant chemotherapy is regarded as the standard of care for patients with stage III colon cancer. However, whether longer treatment can improve prognosis has not been fully investigated. We conducted a phase III study comparing 6 and 12 months of adjuvant capecitabine chemotherapy for stage III colon cancer, and report here the results of our preplanned safety analysis. METHODS: Patients aged 20-79 years with curatively resected stage III colon cancer were randomly assigned to receive 8 cycles (6 months) or 16 cycles (12 months) of capecitabine (2500 mg/m(2)/day on days 1-14 of each 21-day cycle)...
January 11, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28073683/mutant-allele-tumor-heterogeneity-scores-correlate-with-risk-of-metastases-in-colon%C3%A2-cancer
#7
Ashwani Rajput, Thèrése Bocklage, Alissa Greenbaum, Ji-Hyun Lee, Scott A Ness
BACKGROUND: Colorectal cancer is a leading cause of cancer-related mortality, has a very broad mutational spectrum, and there is no clinically available biomarker that can predict which patients with stage II or stage III colorectal cancer will develop metastatic disease. PATIENTS AND METHODS: We used a targeted next-generation sequencing approach to analyze the mutational spectra in stage II and III colon cancer patient samples. RESULTS: Amidst a broad range of acquired mutations and variants, we found evidence of tumor heterogeneity that distinguished the tumors in different groups...
November 23, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28056465/the-impact-of-age-on-complications-survival-and-cause-of-death-following-colon-cancer-surgery
#8
Christopher T Aquina, Supriya G Mohile, Mohamedtaki A Tejani, Adan Z Becerra, Zhaomin Xu, Bradley J Hensley, Reza Arsalani-Zadeh, Francis P Boscoe, Maria J Schymura, Katia Noyes, John Rt Monson, Fergal J Fleming
BACKGROUND: Given scarce data regarding the relationship among age, complications, and survival beyond the 30-day postoperative period for oncology patients in the United States, this study identified age-related differences in complications and the rate and cause of 1-year mortality following colon cancer surgery. METHODS: The NY State Cancer Registry and Statewide Planning and Research Cooperative System identified stage I-III colon cancer resections (2004-2011)...
January 5, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28050138/adjuvant-systemic-chemotherapy-for-stages-ii-and-iii-colon-cancer-after-complete-resection-a-clinical-practice-guideline
#9
B M Meyers, R Cosby, F Quereshy, D Jonker
BACKGROUND: Updated practice guidelines on adjuvant chemotherapy for completely resected colon cancer are lacking. In 2008, Cancer Care Ontario's Program in Evidence-Based Care developed a guideline on adjuvant therapy for stages ii and iii colon cancer. With newer regimens being assessed in this patient population and older agents being either abandoned because of non-effectiveness or replaced by agents that are more efficacious, a full update of the original guideline was undertaken...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28041973/prognostic-significance-of-stromal-grem1-expression-in-colorectal-cancer
#10
Bo Gun Jang, Hye Sung Kim, Weon Young Chang, Jeong Mo Bae, Hyeon Jeong Oh, Xianyu Wen, Seorin Jeong, Nam Yun Cho, Woo Ho Kim, Gyeong Hoon Kang
Cancer associated fibroblasts (CAFs) are the dominant cell population in the cancer stroma. Gremlin 1 (GREM1), an antagonist of the bone morphogenetic protein pathway, is expressed by CAFs in a variety of human cancers. However, its biological significance for cancer patients is largely unknown. We applied RNA in situ hybridization (ISH) to evaluate the prognostic value of stromal GREM1 expression in a large cohort of 670 colorectal cancers (CRCs). Overall GREM1 expression in CRCs was lower than that of the matched normal mucosa, and GREM1 expression had a strong positive correlation with BMI1 and inverse correlations with EPHB2 and OLFM4...
December 29, 2016: Human Pathology
https://www.readbyqxmd.com/read/28040692/prognostic-value-of-braf%C3%A2-and%C3%A2-kras%C3%A2-mutations-in-msi-and-mss-stage-iii-colon-cancer
#11
Julien Taieb, Karine Le Malicot, Qian Shi, Frédérique Penault Lorca, Olivier Bouché, Josep Tabernero, Enrico Mini, Richard M Goldberg, Gunnar Folprecht, Jean Luc Van Laethem, Daniel J Sargent, Steven R Alberts, Jean Francois Emile, Pierre Laurent Puig, Frank A Sinicrope
BACKGROUND: The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/- cetuximab in two adjuvant therapy trials. METHODS: Three groups were defined: BRAF Mutant, KRAS Mutant, and double wild-type...
May 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28039449/expression-analysis-of-microrna-as-prognostic-biomarkers-in-colorectal-cancer
#12
Jie Yang, Dongling Ma, Andrew Fesler, Haiyan Zhai, Apisri Leamniramit, Wenzhe Li, Song Wu, Jingfang Ju
microRNA (miRNA) based biomarkers have unique advantages due to their critical regulatory function, superior stability, and relatively small number compared to mRNAs. A number of miRNAs play key roles in colon cancer stem cell chemoresistance and have clinical potential as prognostic biomarkers. The purpose of this study is to systematically validate the prognostic potential of miRNAs in colorectal cancer. In this study, we validated the prognostic potential of a panel of miRNAs using 205 stage II, III, and IV colorectal cancer specimens by qRT-PCR analysis...
December 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/28035252/signet-ring-colorectal-carcinoma-do-we-need-to-improve-the-treatment-algorithm
#13
Anup Sunil Tamhankar, Parag Ingle, Reena Engineer, Munita Bal, Vikas Ostwal, Avanish Saklani
AIM: To elaborate about this peculiar variant from a tertiary cancer center from India. METHODS: It's a retrospective study (2011-2014) of all patients diagnosed with signet ring colo-rectal cancer (SRCC). Various clinico-pathological variables were studied. RESULTS: One hundred and seventy consecutive patients with SRCC were diagnosed (11.4% of all colorectal cancers). Median Age of the cohort was 41 years. Most common location was recto-sigmoid area (54...
December 15, 2016: World Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28031175/adjuvant-folfox-cetuximab-in-full-ras-and-braf-wildtype-stage-iii-colon-cancer-patients
#14
J Taieb, R Balogoun, K Le Malicot, J Tabernero, E Mini, G Folprecht, J-L Van Laethem, J-F Emile, C Mulot, S Fratté, C-B Levaché, L Saban-Roche, J Thaler, L N Petersen, J Bridgewater, G Perkins, C Lepage, E Van Cutsem, A Zaanan, P Laurent-Puig
BACKGROUND: RAS mutations have been shown to confer resistance to anti-EGFR treatment. We analyzed the results of the PETACC8 trial (cetuximab + FOLFOX vs FOLFOX) in full RAS and BRAF wildtype (WT) patients (pts) with resected stage III colon cancer. METHODS: Exons 2, 3 and 4 of KRAS and NRAS, and BRAF exons 11 and 15, were sequenced using the Ampliseq colon-lung cancer panel version 2, in PETACC8 trial pts who consented to translational research. The impact of cetuximab on time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS) was investigated in pts with tumors harboring RAS & BRAF WT and RAS mutations...
December 28, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28029449/perioperative-fluid-status-and-surgical-outcomes-in-patients-undergoing-cytoreductive-surgery-for-advanced-epithelial-ovarian-cancer
#15
M G Desale, E J Tanner, A K Sinno, A Africano Angarita, A N Fader, R L Stone, K L Levinson, R E Bristow, K Long Roche
OBJECTIVE: The objective of this study is to investigate the impact of fluid status on perioperative outcomes of patients undergoing cytoreductive surgery (CRS) for advanced epithelial ovarian cancer (EOC). METHODS: Patients undergoing CRS for stage III or IV EOC at a comprehensive cancer center from 12/2010 to 05/2015 were identified. Those who underwent upper abdominal procedures or colon resections were included. Demographic, perioperative, and 30-day complication data were collected...
October 28, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/28027818/laparoscopic-colectomy-for-cancer-improved-compliance-with-guidelines-for-chemotherapy-and-survival
#16
Roger H Kim, Mindie M Kavanaugh, Gloria C Caldito
BACKGROUND: Laparoscopic surgery for colon cancer has been demonstrated in clinical trials to have short-term benefits when compared to the open surgical approach. Guidelines of the National Comprehensive Cancer Network recommend that patients with stage III or high-risk stage II colon cancer undergo adjuvant chemotherapy. We hypothesized that laparoscopic colectomy is associated with increased compliance to recommendations for chemotherapy, a lesser time to start of chemotherapy, and increased overall survival...
December 24, 2016: Surgery
https://www.readbyqxmd.com/read/28011386/curcumin-inhibits-growth-potential-by-g1-cell-cycle-arrest-and-induces-apoptosis-in-p53-mutated-colo-320dm-human-colon-adenocarcinoma-cells
#17
Jade Dhananjay Dasiram, Ramamoorthi Ganesan, Janani Kannan, Venkatesan Kotteeswaran, Nageswaran Sivalingam
Curcumin, a natural polyphenolic compound and it is isolated from the rhizome of Curcuma longa, have been reported to possess anticancer effect against stage I and II colon cancer. However, the effect of curcumin on colon cancer at Dukes' type C metastatic stage III remains still unclear. In the present study, we have investigated the anticancer effects of curcumin on p53 mutated COLO 320DM human colon adenocarcinoma cells derived from Dukes' type C metastatic stage. The cellular viability and proliferation were assessed by trypan blue exclusion assay and MTT assay, respectively...
December 20, 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28010880/assessing-the-national-trends-in-colon-cancer-among-native-americans-a-12-year-seer-database-study
#18
R Thuraisingam, J Jandova, V Pandit, M Michailidou, V N Nfonsam
INTRODUCTION: Native Americans (NA) form a unique cohort of colon cancer (CC) patients among whom the variability in demographics and cancer characteristics remains unclear. METHODS: We abstracted the national estimates for NA with CC using the Surveillance, Epidemiology, and End Result (SEER) database. Trend analysis of incidence, variation in location and patient demographic analysis were performed. RESULTS: A total number of 26,674 NA with CC were reported during the 12-year study period...
November 22, 2016: American Journal of Surgery
https://www.readbyqxmd.com/read/28006840/copy-number-variations-in-dcc-18q-and-erbb2-17q-are-associated-with-disease-free-survival-in-microsatellite-stable-colon-cancer
#19
David Sefrioui, Thomas Vermeulin, France Blanchard, Caroline Chapusot, Ludivine Beaussire, Laura Armengol-Debeir, Richard Sesboué, Alice Gangloff, Mohamed Hebbar, Marie-Christine Copin, Estelle Houivet, Lilian Schwarz, Florian Clatot, Jean-Jacques Tuech, Jacques Bénichou, Laurent Martin, Anne-Marie Bouvier, Jean-Christophe Sabourin, Nasrin Sarafan-Vasseur, Thierry Frébourg, Côme Lepage, Pierre Michel, Frédéric Di Fiore
We conducted a prospective study to assess the prognostic impact of selected copy number variations (CNVs) in stage II-III microsatellite stable (MSS) colon cancer. A total of 401 patients were included from 01/2004 to 01/2009. The CNVs in 8 selected target genes, DCC/18q, EGFR/7p, TP53/17p, BLK/8p, MYC/8q, APC/5q, ERBB2/17q, and STK6/20q, were detected using a quantitative multiplex polymerase chain reaction of short fluorescent fragment (QMPSF) method. The primary end-point was the impact of the CNVs on the 4-year disease-free survival (DFS)...
December 22, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28006055/association-of-dna-mismatch-repair-and-mutations-in-braf-and-kras-with-survival-after-recurrence-in-stage-iii-colon-cancers-a-secondary-analysis-of-2-randomized-clinical-trials
#20
Frank A Sinicrope, Qian Shi, Carmen J Allegra, Thomas C Smyrk, Stephen N Thibodeau, Richard M Goldberg, Jeffrey P Meyers, Kay L Pogue-Geile, Greg Yothers, Daniel J Sargent, Steven R Alberts
Importance: The association of biomarkers with patient survival after recurrence (SAR) of cancer is poorly understood but may guide management and treatment. Objective: To determine the association of DNA mismatch repair (MMR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy...
December 22, 2016: JAMA Oncology
keyword
keyword
59219
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"